The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumbar Discogenic Pain

Inclusion Criteria: 1. age over 18 2. refractory and persistent lumbago pain for more than 6 months, with/without radiation pain in lower limbs, and poor conservative treatment effect; 3. the straight leg elevation test was 70 degrees negative; 4. MRI of lumbar spine showed herniated disc \< 6 mm, no obvious compression of spinal cord and nerve roots; T2-weighted mri of the lumbar spine showed decreased single/multi-segment signal (black disc sign) or High signal zone (HIZ) in the posterior part of the intervertebral disc annulus. 5. clinical signs of nerve localization were consistent with MRI changes; 6. subject gives informed consent and signs informed consent. Exclusion Criteria: 1. coagulation dysfunction or anticoagulant therapy; 2. intervertebral space infection, puncture site infection or systemic infection; 3. lumbago pain of non-spinal origin, such as sacroiliac joint origin pain; 4. patients who have had open surgery or other disc treatments; 5. imaging examination suggested disc prolapse, prolapse, spinal canal bone stenosis, etc.; 6. patients with vital organ system dysfunction and tumor lumbar vertebra metastasis; 7. subjects with high tumor markers (AFP/CEA/CA199/CA125); 8. the subject is pregnant or breastfeeding; 9. subjects also receive other treatments that may affect the efficacy and safety of stem cells; 10. failing to control alcohol and other substance abuse during the 6 months prior to enrollment and enrollment period; 11. the subjects suffer from mental illness, or lack of understanding, communication and cooperation, and cannot be guaranteed to follow the study protocol; Subjects who are not willing to sign informed consent and are participating in other clinical trials or have participated in other clinical trials within 3 months;